Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
UK and USA-based clinical stage biotech F-star Therapeutics today announced a license and collaboration agreement with Janssen Biotech, a subsidiary of US healthcare giant of Johnson & Johnson. 20 October 2021
Biotechnology
Drug price disruptor EQRx has signed a memorandum of understanding (MoU) with the UK’s National Health Service, outlining plans for a long-term partnership to supply medicines. 20 October 2021
Biotechnology
German family-owned pharma major Boehringer Ingelheim today said it has exercised its option to license UK-based Oxford Biomedica’s lentiviral vector technology to manufacture, register and commercialize BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF). 19 October 2021
Pharmaceutical
Californian precision oncology company Calithera Biosciences has padded its pipeline with two assets from Japanese giant Takeda Pharmaceutical. 19 October 2021
Pharmaceutical
Shares of USA-based antibacterial products developer Entasis Therapeutics were up 27% at $3.95 pre-market, as the company announced positive top-line results from its ATTACK trial - a global Phase III registrational trial evaluating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii. 19 October 2021
Pharmaceutical
Physics-based US software specialist Schrödinger and Centessa Pharmaceuticals, together with the latter’s subsidiary Orexia Therapeutics, today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R). 18 October 2021
Biotechnology
Shares of UK-based Silence Therapeutics were up as much as 6.5% at 556.50 pence this morning, after it revealed the signing of a potential $1.3 billion accord. 15 October 2021
Biotechnology
London-listed blood disease specialist Hemogenyx Pharmaceuticals has signed a license agreement with US pharma major Eli Lilly. 13 October 2021
Biotechnology
Dutch antibody-drug conjugate (ADC) specialist Synaffix today presented new data regarding its topoisomerase 1 inhibitor linker-payload based on exatecan (SYNtecan E), at the World ADC Conference, showing excellent in vivo efficacy and tolerability. 13 October 2021
Pharmaceutical
CNS disease specialist Supernus Pharmaceuticals and fellow USA-based Adamas Pharmaceuticals have entered a definitive agreement for Supernus to acquire Adamas, whose share shot up 75% to $8.07 by close of trading on Monday. 12 October 2021
Biotechnology
Ensoma, a Boston, USA-based gene therapy company advancing the future of medicine through precision in vivo engineering of blood and immune cells, today announced the appointment of Emile Nuwaysir as president, chief executive officer and member of the company’s board of directors. 11 October 2021
Biotechnology
Germany-based biotech atai Life Sciences today announced the launch of PsyProtix, a new platform company formed with Chymia, a Duke University biotechnology spinout. 11 October 2021
Biotechnology
Following an evenly split vote from the US regulator’s advisory committee in May this year, there was good news for US biotech ChemoCentryx on Friday, as the US Food and Drug Administration approved the firm’s Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, propelling its shares 69% higher to $33.13. 9 October 2021
Biotechnology
Cambridge, Massachusetts, USA-based biotech Pyxis Oncology made its public debut on Friday after announcing an upside initial public offering IPO), raising $168 million at $16 a share. 9 October 2021
Pharmaceutical
Fortress Biotech subsidiary Cyprium Therapeutics, with support from its licensing partner Sentynl Therapeutics, which is wholly-owned by India’s Cadila Healthcare, today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). 8 October 2021
Pharmaceutical
Swedish drugmaker Calliditas Therapeutics has now taken full control of France-headquartered Genkyotex, a leader in NOX inhibition therapies, after the completion of a centralized squeeze out offer to all minority shareholders. 7 October 2021
Biotechnology
The value of US gene therapy company Voyager Therapeutics doubled in Wednesday’s early trading following news of a deal with the world’s largest pharma company. 6 October 2021
Biotechnology
USA-based microbiome company Vedanta Biosciences says that its Phase II clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent Clostridium difficile infection (CDI) in high-risk patients, met its primary endpoint of preventing disease recurrence through Week 8. 6 October 2021
Biotechnology
Swiss biotech MoonLake Immunotherapeutics and Helix Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, today announced they have entered into a definitive business combination agreement. 4 October 2021
Pharmaceutical
Shares of Ireland-incorporated drugmaker Cosmo Pharmaceuticals fell 4.4% to 76 Swiss francs this morning after it revealed it has agreed to buy back Italy-based Cassiopea, the dermatologics company it spun out in 2015. 4 October 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze